WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H125658
CAS#: 2305750-23-4
Description: IM-250 is a potent HSV-1 helicase primase inhibitor. Therapy of primary HSV infections with IM-250 not only reduces the duration of disease symptoms or time to healing but also prevents recurrent disease in guinea pigs. Treatment of recurrent infections reduces the frequency of recurrences and viral shedding, and, unlike nucleosidic drugs, IM-250 remains effective for a time after cessation of treatment. Hence, IM-250 has advantages over standard-of-care therapies and represents a promising therapeutic for chronic HSV infection, including nucleoside-resistant HSV. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.
Hodoodo Cat#: H125658
Name: IM-250
CAS#: 2305750-23-4
Chemical Formula: C20H19F2N3O2S2
Exact Mass: 435.09
Molecular Weight: 435.510
Elemental Analysis: C, 55.16; H, 4.40; F, 8.72; N, 9.65; O, 7.35; S, 14.72
Synonym: IM-250; IM 250; IM250
IUPAC/Chemical Name: (S)-2-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-(S-methylsulfonimidoyl)thiazol-2-yl)acetamide
InChi Key: JDZTWDISDHLKCR-LJAQVGFWSA-N
InChi Code: InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3/t29-/m0/s1
SMILES Code: O=C(N(C)C1=NC(C)=C([S@](=N)(C)=O)S1)CC2=CC=C(C3=CC(F)=CC=C3F)C=C2
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 435.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Bernstein DI, Sawtell NM, Bravo FJ, Dixon DA, Gege C, Kleymann G. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV. Antiviral Res. 2023 Nov;219:105733. doi: 10.1016/j.antiviral.2023.105733. Epub 2023 Oct 18. PMID: 37858763.
2: Gege C, Kleymann G. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037. Expert Opin Ther Pat. 2022 Sep;32(9):933-937. doi: 10.1080/13543776.2022.2113873. Epub 2022 Aug 19. PMID: 35965439.
3: Spahn S, Riessen R, Berg CP, Malek NP, Emrich MH, Lohrengel K, Ganzenmueller T, Iftner T, Kleymann G, Hamprecht K. Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary infection. Liver Int. 2022 May;42(5):1005-1011. doi: 10.1111/liv.15215. Epub 2022 Mar 7. PMID: 35230726.
4: Uhlig N, Donner AK, Gege C, Lange F, Kleymann G, Grunwald T. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. 2021 Nov;195:105190. doi: 10.1016/j.antiviral.2021.105190. Epub 2021 Oct 16. PMID: 34666109.
5: Gege C, Bravo FJ, Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, Burger- Kentischer A, Finkelmeier D, Hamprecht K, Grunwald T, Bernstein DI, Kleymann G. A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections. Sci Transl Med. 2021 Jun 16;13(598):eabf8668. doi: 10.1126/scitranslmed.abf8668. PMID: 34135112.
